evipedia.ai
← Back

Ecdysteroids for Health & Longevity

Evidence Review created on 09/20/2026 using AI4L / Opus 5

Also known as: 20-Hydroxyecdysone, Ecdysterone, β-Ecdysone, β-Ecdysterone, Turkesterone, Phytoecdysteroids, 20E, BIO101

Motivation

Ecdysteroids are steroid-like compounds that insects and crustaceans use to trigger molting, and that many plants make to deter the insects feeding on them. Spinach, quinoa, asparagus and several Central Asian roots all contain them. Interest in humans rests on a simple observation: these molecules appear to push muscle tissue to build protein without touching the male hormone receptors that conventional anabolic steroids act on, which would in principle separate the muscle effect from the hormonal side effects.

Two very different worlds have taken them up. Soviet and Russian sports medicine used root extracts rich in these compounds for decades to reduce fatigue and support training, and they are now sold widely as muscle-building supplements. Separately, a purified pharmaceutical version has been carried through formal trials in older adults losing muscle and in hospital patients with severe lung illness.

This review examines what the human and animal evidence shows about ecdysteroids for health and longevity: the proposed mechanisms, the size and quality of the clinical record, the safety signals, the product-quality problems, and what remains unresolved.

Benefits - Risks - Protocol - Conclusion

This section collects high-level sources that explain what ecdysteroids are, what the human record actually contains, and where the practical hazards lie.

Note on priority sources: none of the six priority platforms carries a dedicated article, episode or lecture on ecdysteroids. Found My Fitness mentions turkesterone only inside a research digest about supplement mislabeling, and Huberman Lab covers ecdysteroids only in two short timestamped segments inside broader episodes, one in a guest episode on hormone optimisation and one in a solo episode on testosterone and estrogen; neither platform treats the compound class in substantial depth, so neither was listed. Peter Attia, Chris Kresser, Life Extension and Lifespan.io returned no on-topic content at all. Five qualifying sources were found, so the list is complete and has not been padded.

Grokipedia

Ecdysteroid

Covers the chemical class, its hormonal role in arthropods, plant occurrence and the mammalian pharmacology debate in one place, with separate linked entries for 20-hydroxyecdysone and turkesterone.

Examine

Ecdysteroids

Grades the evidence base at a single trial with 45 participants across body composition, muscle size and strength, and athletic performance, making the thinness of the human record immediately visible.

ConsumerLab

No ConsumerLab article exists for ecdysteroids. ConsumerLab has not tested ecdysterone or turkesterone products, so no independent potency or purity results are available from this source.

Systematic Reviews

This section lists the systematic reviews and meta-analyses bearing on ecdysteroids, all of which pool preclinical rather than human data.

Trade-off coverage: the claimed-benefit side is unrepresented — no systematic review or meta-analysis has pooled human trials of ecdysteroid supplementation for muscle, metabolic or functional outcomes. The principal-risk side is represented only indirectly, through the toxicology chapter of the Ajuga review; no systematic review addresses the safety of marketed ecdysteroid products in humans.

Mechanism of Action

Ecdysteroids are polyhydroxylated steroids built on a cholesterol skeleton, but their hydroxyl pattern prevents them binding the mammalian androgen receptor (the male-hormone receptor). Two alternative routes are proposed. The first is estrogen receptor beta (a nuclear receptor that switches on muscle-growth genes); blocking it abolishes ecdysterone-driven enlargement of cultured muscle fibres and of rat muscle (Parr et al., 2014). The second is the Mas1 receptor (a cell-surface receptor of the renin-angiotensin system, the hormone network governing blood pressure and fluid balance), whose protective arm opposes muscle wasting and inflammation (Dinan et al., 2021). Both converge on PI3K-Akt-mTOR signalling (the cascade instructing muscle cells to build protein) and on calcium entry, raising protein synthesis without shifting circulating testosterone or estradiol.

Pharmacologically the compound is short-acting and poorly retained. Plasma half-life is 2.4-4.9 hours, exposure rises less than dose-proportionally above roughly 100 mg, renal clearance is 4.05-5.05 L/h, and twice-daily dosing accumulates only 1.3-fold over two weeks (Dioh et al., 2023). Distribution is broad rather than targeted, with no tissue depot identified. Metabolism runs through gut-bacterial removal of one hydroxyl group and side-chain cleavage (Piper & Thevis, 2023), with no evidence of meaningful involvement of cytochrome P450 (the liver enzyme family that clears most drugs).

A competing reading holds that nothing survives at achievable exposures: phytoecdysteroids changed neither muscle mass nor protein-synthesis signalling in aging mice (Lawrence et al., 2021).

Historical Context & Evolution

Ecdysteroids were isolated from silkworm pupae in the 1950s and identified as the hormones driving insect molting; the structure of 20-hydroxyecdysone was published in 1966 (Hoffmeister, 1966). The original intended use was entirely entomological — a tool for studying metamorphosis and, later, a template for the insect growth regulators sold as insecticides.

The turn toward human performance came from Soviet pharmacology in the 1970s and 1980s. Groups in Uzbekistan and Russia reported that ecdysterone raised protein synthesis in rat skeletal muscle and improved physical endurance (Chermnykh et al., 1988), in direct comparison performing comparably to methandrostenolone (an anabolic-androgenic steroid). Maral root preparations were classified in 1969 as adaptogens (plants held to raise general resistance to stress) and became routine in Soviet sport. Much of that literature is Russian-language and unblinded, and it has rarely been replicated; it has also not been formally refuted, and the primary reports describe measured protein-synthesis and endurance outcomes rather than impressions.

Western uptake happened twice and separately. Supplement manufacturers adopted the compounds in the 2000s as “natural anabolics”, while pharmaceutical development of a purified preparation began around 2010 for age-related muscle loss. Opinion has since moved in both directions: anti-doping science shifted from dismissal to placing ecdysterone under formal monitoring in 2020 after a controlled human trial, whereas a well-controlled rodent experiment in 2021 found no anabolic effect at all (Lawrence et al., 2021).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no outcome — muscle mass, physical function or metabolic marker — has been reproduced in more than one controlled human trial, and the one outcome tested repeatedly, muscle growth during resistance training, is directly conflicted.

Medium 🟩 🟩

Purified 20-hydroxyecdysone at 350 mg twice daily improved 400-metre walking speed in community-dwelling adults aged 65 and over with sarcopenia (age-related loss of muscle mass and strength), with the effect also seen in slow walkers, obese participants and those with the weakest chair-stand scores. It reached significance only in the per-protocol population (meaning participants who completed treatment as planned); the pandemic cost the trial 55% of its end-of-treatment assessments. This single phase 2b trial was run and co-authored by Biophytis, which owns the compound.

Magnitude: +0.09 m/s in 400-metre gait speed versus placebo in the per-protocol population (p = 0.008, where p is the probability that a difference this large would appear by chance alone) and +0.07 m/s in the full analysis set (everyone randomised; not statistically significant), against a minimal clinically important difference (the smallest change people notice) of 0.1 m/s (Fielding et al., 2025).

Insulin Sensitivity and Regional Fat Loss Alongside Resistance Training

Asparagus-derived 20-hydroxyecdysone at 30 mg daily for 12 weeks, combined with supervised resistance training, lowered fasting insulin and free fatty acids, raised an insulin-sensitivity index and increased fat oxidation at rest and during light exercise in trained young men. Arm fat fell significantly more than in the placebo group; leg and abdominal fat fell within-group only. This is one small double-blind trial of 20 participants in an already-lean population, so the between-group signal is narrow and its durability untested.

Magnitude: direction only — arm fat falls and fat oxidation rises further than on placebo, the between-group advantage holding at 40% of peak oxygen uptake, with fasting insulin and plasma free fatty acids falling and the quantitative insulin sensitivity check index rising within the treated group; the accessible trial record reports significance levels alone and gives no outcome figure (Sripinyowanich et al., 2025).

Reduced Respiratory Failure and Death in Severe Viral Pneumonia

In hospitalised adults with severe COVID-19, oral 20-hydroxyecdysone at 350 mg twice daily for up to 28 days cut the combined rate of respiratory failure or early death, with a smaller and non-significant reduction in 90-day mortality and more respiratory-failure adverse events in the placebo arm. The proposed mechanism is Mas1-receptor activation restoring balance in the renin-angiotensin system. Recruitment stopped short of target, and the sponsor, Biophytis, funded the trial and supplied most of the writing group.

Magnitude: respiratory failure or early death by day 28 in 13.5% on treatment versus 24.3% on placebo, an absolute reduction of 11.4% (p = 0.0426); hazard ratio for death over 90 days (the relative rate of dying over that period) was 0.554, with a 95% confidence interval of 0.285-1.077 (the range within which the true value most likely lies) (Lobo et al., 2024).

Clearance of Intestinal Giardia Infection

Oral 20-hydroxyecdysone at 200 mg daily for 10 days cleared Giardia lamblia from every treated athlete in a randomised, double-blind, placebo-controlled trial, matching metronidazole, the standard antibiotic for this infection. The proposed basis is direct antiprotozoal activity, unrelated to the muscle pathway. This is a single trial of 76 water-sports athletes from one Uzbek group, in a narrow population, and no independent replication exists.

Magnitude: 100% of treated athletes cleared Giardia lamblia after 10 days, against a 4% treatment failure rate in the metronidazole arm (Toychiev et al., 2022).

Low 🟩

Muscle Mass and Strength Gains with Resistance Training ⚠️ Conflicted

One 10-week trial in 46 young men found larger muscle-mass and bench-press gains on verified ecdysterone, and a 12-week trial in 45 adults over 50 found greater strength gains at a lower dose; two other trials found none. Net reading: two verified trials favour a modest effect, two do not.

Magnitude: roughly 9-10 kg gain in bench-press one-repetition maximum (the heaviest single lift achievable) over 10 weeks versus about 3 kg on placebo, with lean-mass gains up to about 2 kg, at verified doses of 12 mg and 48 mg daily (Isenmann et al., 2019); greater between-group improvement in knee-extension peak torque and muscle quality over 12 weeks on 2 g daily of a standardised spinach extract in adults over 50, reported as significance levels without effect sizes (Pérez-Piñero et al., 2021); no group difference in strength or lean mass at 12 weeks when the product held under 1% of its claimed content (Dissemond et al., 2025); and no difference at 8 weeks on 200 mg daily of an unassayed product (Wilborn et al., 2006).

Speculative 🟨

Antioxidant and Anti-Inflammatory Response to Training

Asparagus root extract supplying about 1.7 mg/kg daily plus interval training lowered inflammation and oxidative-damage markers in overweight adults (Prasertsri et al., 2025). Those markers are unvalidated laboratory measures, not clinical outcomes.

Bone Density Preservation

β-Ecdysterone drives bone-forming cell differentiation and speeds bone regeneration in rodents (Yan et al., 2022). The basis is animal work only; no human bone-density or fracture data exist at any dose.

Nerve Protection and Cognitive Resilience

Ecdysterone reduced amyloid-driven nerve-cell toxicity and improved memory in mice by strengthening antioxidant defences (Xing et al., 2024). The basis is animal and cell-culture work only; no human cognitive trial exists.

Liver Fat and Blood Lipid Reduction

20-Hydroxyecdysone reduced liver fat, white fat mass and high blood sugar in obese and hormone-depleted rodents (Buniam et al., 2023). No controlled human liver or lipid endpoint has been reported.

Healthspan Extension and Stress Resilience

Maral root extract and its ecdysterone fraction extended lifespan and improved stress resistance and fitness in nematodes (Todorova et al., 2025). Invertebrate lifespan work carries no human longevity implication on its own.

Fatigue Resistance and Physical Endurance

Soviet reports describe reduced fatigue and greater endurance, and rat work found endurance gains comparable to an anabolic steroid (Chermnykh et al., 1988). No controlled human endurance trial exists.

Benefit-Modifying Factors

  • Gut microbiome composition: the first metabolic step is bacterial, so an individual’s gut flora shapes how much parent compound and how much metabolite reaches tissue, plausibly explaining part of the wide between-person variation in urinary recovery (Piper & Thevis, 2023).

  • Estrogen receptor beta polymorphisms: because the proposed anabolic route runs through this receptor, common variants altering its expression are a plausible determinant of response. No genotype-stratified human study has tested this, so the factor is mechanistic rather than demonstrated.

  • Baseline training status and muscle reserve: every positive human signal appeared in people actively training or rehabilitating. Sedentary aging mice showed none at all (Lawrence et al., 2021), suggesting the compound amplifies a growth stimulus rather than creating one.

  • Baseline insulin and body-fat levels: the metabolic benefits were recorded in people with room to move — raised fasting insulin, higher regional fat. Subgroup effects in the sarcopenia trial were also largest in obese participants, so lean and insulin-sensitive individuals have less headroom.

  • Sex: no sex difference in urinary elimination has been detected (Ambrosio et al., 2021), and the sarcopenia trial enrolled 54% women without reporting a sex interaction. The muscle trials enrolled men only, so the effect size in women is unmeasured.

  • Age: plasma exposure is 13-22% lower in adults over 65 than in young adults, yet the clearest functional benefit was recorded in that older group. At the older end of the target range, lower exposure has not translated into lower benefit.

  • Pre-existing health conditions: obesity, slow gait and weak chair-stand performance each predicted larger functional gains. Conditions that were exclusion criteria — significant kidney or liver impairment, hormone-sensitive cancer — leave response in those groups entirely unmeasured.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Across the phase 1, sarcopenia and pneumonia trials the pharmaceutical-grade compound produced only mild-to-moderate adverse events, chiefly gastrointestinal, with no dose-limiting toxicity up to 1400 mg as a single dose or 450 mg twice daily for 14 days (Dioh et al., 2023). Liver and kidney markers did not deteriorate in the resistance-training trial either (Isenmann et al., 2019). The honest reading is that the measurable side-effect burden is low and, in the sarcopenia trial, numerically lower than placebo — but total exposure is capped at nine months.

Magnitude: treatment-related adverse events in 13.3% at 175 mg twice daily and 13.5% at 350 mg twice daily, versus 16.0% on placebo, over six to nine months (Fielding et al., 2025).

Medium 🟥 🟥

Contamination with Prohibited or Unapproved Substances

Marketed ecdysteroid products are frequently adulterated. Roughly one in five tested ecdysterone supplements carried impurities including prohibited anabolic substances, and independent testing of sports supplements containing turkesterone found banned stimulants and unapproved drugs. Because ecdysterone itself sits on the World Anti-Doping Agency monitoring programme rather than the prohibited list, a positive test almost always traces to an undeclared contaminant, not the labelled ingredient. Consequences run from a career-ending sanction to unintended exposure to androgenic steroids carrying genuine hormonal and liver risk.

Magnitude: nearly 20% of tested ecdysterone supplements carried impurities including prohibited anabolic substances and more than 28% of analysed sports supplements posed a risk of unintentional doping; an estimated 6.4-8.8% of positive doping cases are attributed to contaminated supplements (Dissemond et al., 2025).

Low 🟥

Exertional Rhabdomyolysis in Multi-Ingredient Stacks

A 23-year-old man developed rhabdomyolysis (breakdown of muscle fibres releasing their contents into the blood) after a four-hour training session while taking β-ecdysterone alongside creatine, β-alanine and citrulline malate. Causation cannot be assigned to any single ingredient. This is a single case report.

Magnitude: creatine kinase (the enzyme released when muscle fibres rupture) exceeded 120,000 U/L, with the liver enzymes aspartate aminotransferase at 1,275 U/L and alanine aminotransferase at 337 U/L, resolving over 10 days on intravenous fluids without kidney injury (Chowaniec et al., 2026).

Speculative 🟨

Unstudied Safety in Pregnancy, Lactation and Adolescence

No ecdysteroid trial has enrolled pregnant or breastfeeding women or under-18s; toxicology covers rats and dogs only (Dinan et al., 2021). The basis is mechanistic — estrogen receptor beta is central to development.

Androgen-Balance Shifts

Phytoecdysteroids unexpectedly altered androgen balance in normal and obese rats while preventing diet-induced obesity (Osman et al., 2026). Human trials measuring the steroid profile found no change, so this rests on animal data alone.

Estrogen Receptor Beta Activity in Hormone-Sensitive Tissue

Because the anabolic route runs through estrogen receptor beta, effects on hormone-sensitive tissue are conceivable. Cell work points the other way — ecdysterone inhibited breast cancer cell growth (Shuvalov et al., 2020). The basis is mechanistic.

Additive Blood-Pressure Lowering

Activating the protective arm of the renin-angiotensin system could lower blood pressure further in people already taking agents acting there (Dinan et al., 2021). No trial observed this; the basis is mechanistic.

Risk-Modifying Factors

  • Product provenance: the dominant risk variable is the container, not the molecule. Products built from undeclared Cyanotis arachnoidea extract sold as spinach extract carry unknown co-extracted compounds and the highest contamination exposure; certified pharmaceutical-grade material carries the lowest.

  • Concurrent supplement stacking: the one documented serious event occurred in a five-supplement stack during extreme exertion. Each added performance ingredient widens the range of possible interactions and makes attribution of any adverse event effectively impossible.

  • Competitive testing status: tested athletes carry a risk no one else does. Ecdysterone is monitored rather than banned, so the hazard is contamination with listed substances — a sanction risk entirely absent for recreational users.

  • Genetic polymorphisms: no variant has been shown to modify risk. Because clearance runs through gut bacteria and the kidney rather than cytochrome P450, the common drug-metabolising variants that alter toxicity for many agents are unlikely to apply here.

  • Baseline liver and kidney function: trials excluded significant organ impairment, so clearance in that setting is unmeasured. Renal clearance accounts for a substantial share of elimination, making reduced kidney function the likeliest source of unexpected accumulation.

  • Baseline hormone and muscle-enzyme levels: a raised resting creatine kinase or an already-suppressed testosterone reading removes the reference point needed to interpret any later change, and masks whether a shift came from the compound or from training.

  • Pre-existing hormone-sensitive conditions: activity at estrogen receptor beta has produced no clinical hormonal signal, but people with estrogen-responsive cancers were excluded from every trial, so risk in that group is undetermined rather than absent.

  • Sex and age: no sex difference in elimination or adverse-event pattern has been reported. Adults over 65 show modestly lower plasma exposure with no increase in adverse events; the largest safety dataset in any group comes from that age band.

Key Interactions & Contraindications

  • Renin-angiotensin system agents (lisinopril, ramipril, losartan, valsartan): caution. Shared signalling through the protective arm of that system could add to blood-pressure lowering. Blood-pressure monitoring for two weeks after starting is the usual mitigation; separated dosing is not required.

  • Glucose-lowering drugs (metformin, glipizide, insulin, semaglutide): caution, with potential additive reduction in fasting glucose and insulin. More frequent home glucose monitoring for four weeks, and dose reduction of the glucose-lowering agent if readings drift low, are the standard mitigations.

  • Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, the common painkillers): monitor. No direct interaction is described, but both add kidney strain during the prolonged heavy exertion that accompanied the single reported case of severe muscle breakdown.

  • Over-the-counter stimulant and thermogenic products (caffeine, synephrine, yohimbine): caution. The hazard is formulational rather than pharmacological — ecdysteroid products are frequently sold inside stimulant blends, compounding the contamination risk documented for that category.

  • Creatine, β-alanine and citrulline malate: monitor. This exact stack accompanied the single reported case of severe muscle breakdown during prolonged training. No mechanistic interaction is established; the concern is cumulative tolerance of training load.

  • Blood-pressure-lowering supplements (beetroot nitrate, garlic extract, magnesium): caution, since additive blood-pressure reduction is plausible given the proposed receptor mechanism. Staggering introduction by two weeks keeps any drop attributable to one agent.

  • Diosgenin-containing products (fenugreek, wild yam extract): monitor. Cell work shows ratio-dependent additive muscle effects, and the only human test of the pair was invalidated by near-absent active content, so the combined effect in people is unknown.

  • Anabolic-androgenic steroids (testosterone enanthate, nandrolone) and selective androgen receptor modulators (muscle-targeting drugs such as ostarine and ligandrol): caution. Ecdysteroids act outside the androgen receptor, so no receptor competition is expected, but co-use makes any adverse event unattributable and compounds liver and lipid risk.

Populations who should avoid Ecdysteroids:

  • Pregnant and breastfeeding women — no human exposure data at any dose
  • Anyone under 18 years of age — no trial has enrolled adolescents
  • People with active estrogen-receptor-positive breast, endometrial or ovarian cancer — excluded from all trials, with receptor activity unresolved in that setting
  • People with severe kidney impairment, meaning an estimated glomerular filtration rate (a standard measure of filtering capacity) below 30 mL/min/1.73 m² — renal clearance dominates elimination and was never studied in this range
  • People with decompensated liver disease at Child-Pugh Class C (the most severe grade of chronic liver failure) — excluded from the trial programme
  • Athletes subject to anti-doping testing who cannot source a certified batch-tested product

Risk Mitigation Strategies

  • Batch-certified product only: material carrying Informed Sport or NSF Certified for Sport certification is tested batch by batch for the prohibited substances found in roughly one in five ecdysterone supplements, mitigating contamination and sanction risk.

  • Supplier certificate of analysis: an assay showing actual 20-hydroxyecdysone content by mass spectrometry is the only defence against an inert capsule, since marketed products have tested below 1% of their labelled content.

  • Single-ingredient formulations: choosing plain ecdysterone over stimulant or “anabolic matrix” blends keeps any adverse event attributable and cuts exposure to the undeclared stimulants repeatedly found in that product category.

  • Capped training volume during the first four weeks: avoiding sessions beyond 90 minutes and sudden load increases mitigates severe muscle breakdown, the one documented serious event, which followed a four-hour session in a heavily supplemented trainee.

  • Organ-function screening at baseline and 8-12 weeks: alanine aminotransferase, creatinine and creatine kinase together catch the liver, kidney and muscle injury patterns that contaminated products, rather than the compound itself, have produced.

  • Staggered introduction of other blood-pressure or glucose-lowering agents: leaving two weeks either side before adding any such agent keeps an additive drop attributable and mitigates unexplained low blood pressure or low blood sugar.

  • Disclosure to a treating clinician: informing any prescriber, particularly before surgery or before starting drugs acting on the renin-angiotensin system, mitigates the interaction risks that are mechanistically plausible but clinically untested.

Therapeutic Protocol

  • Pharmaceutical-grade regimen: the only schedule validated in a formal trial is 350 mg of purified 20-hydroxyecdysone twice daily for six to nine months, used for age-related muscle loss and severe pneumonia (Fielding et al., 2025).

  • Supplement-practice regimen: users typically target 200-1000 mg daily of labelled ecdysterone, but verified content is the binding constraint; measurable effects appeared at 12-48 mg daily of assayed compound in a content-verified training trial (Isenmann et al., 2019).

  • Split dosing rather than a single dose: the 2.4-4.9 hour half-life leaves most of the day unexposed on once-daily dosing. Every positive clinical trial used twice-daily dosing; three times daily is common in supplement practice.

  • Time of day: no time-of-day advantage is established. Trials dosed morning and evening with food; placing the second dose no later than early evening keeps exposure within waking hours.

  • Taken with food: absorption is saturable above roughly 100 mg and food-borne ecdysterone is poorly absorbed, so dosing with a meal is conventional practice rather than an evidence-based rule.

  • Competing approach — whole-food loading: some practitioners favour spinach and quinoa over isolates. The pharmacology argues against it: only 1-3% of food-borne ecdysterone is absorbed, versus far higher recovery from the pure compound (Isenmann et al., 2024).

  • Competing approach — phytosteroid stacking: formulators pair ecdysterone with diosgenin from fenugreek, on cell-culture evidence of ratio-dependent additive effects (Kostov et al., 2024). No human trial has validated any ratio.

  • Who popularised each approach: Biophytis, a Paris-based biotechnology company, developed the pharmaceutical twice-daily schedule; the German Sport University Cologne and Free University of Berlin group established the content-verified supplement dosing used in research.

  • Genetic polymorphisms: no variant has been shown to alter response or dose. Because clearance runs through gut bacteria and the kidney rather than cytochrome P450, the usual drug-metabolising variants are unlikely to matter here.

  • Sex-based differences: urinary elimination shows no sex difference and no sex-specific dose is used. Efficacy in women is untested for muscle outcomes; the functional trial in older adults enrolled both sexes at the same dose.

  • Age-related adjustment: adults over 65 show 13-22% lower plasma exposure yet tolerated and benefited from the full dose (Dioh et al., 2023). No reduction is indicated on age alone at the older end of the target range.

  • Baseline biomarkers guiding response: higher fasting insulin, higher regional fat and slower gait speed marked the subgroups with the largest effects. Those already lean, insulin-sensitive and fast-walking have less headroom for gain.

  • Pre-existing conditions: obesity and impaired mobility predicted larger functional gains. Significant kidney or liver impairment, hormone-sensitive cancer and pregnancy were exclusion criteria throughout, so no protocol exists for those groups.

Discontinuation & Cycling

  • Intended duration: neither lifelong nor acute. The longest human exposure on record is nine months, and no trial has tested continuous use beyond that, so a defined course rather than indefinite use is what the evidence supports.

  • No withdrawal syndrome reported: no rebound, dependence or withdrawal effect has been described in any trial or case report. The short half-life means the compound clears within roughly a day of the last dose.

  • No taper required: because no suppression of the body’s own sex-hormone production and no receptor downregulation has been reported, abrupt cessation was the norm in every trial. A taper serves no documented purpose.

  • Cycling is not evidence-based: no study has compared continuous with cycled dosing. The patterns circulating in supplement practice — typically 8-12 weeks on, four weeks off — derive from anabolic-steroid conventions rather than from ecdysteroid data.

  • Effect reversal on stopping: functional gains in the sarcopenia trial were measured on treatment only, with no washout follow-up. Whether walking speed or lean mass regresses after cessation is unmeasured.

  • Pragmatic stopping point: if no change in strength, body composition or walking speed is measurable at 12 weeks on a content-verified product, the compound has not worked for that individual and continuing has no evidential basis.

Sourcing and Quality

  • Verified content is the central problem: of 12 supplements assayed, most held far less 20-hydroxyecdysone than labelled (Ambrosio et al., 2020), and a later trial product held under 1% of its claim (Dissemond et al., 2025). Potency cannot be inferred from a label.

  • Species substitution is documented: German products sold as spinach extract were manufactured from Cyanotis arachnoidea, identified by acetate marker compounds. The substituted plant is far richer in ecdysteroids but brings undeclared co-extractives (Hunyadi et al., 2016).

  • What to look for: third-party batch certification (Informed Sport, NSF Certified for Sport), a mass-spectrometry certificate of analysis naming the assayed compound and its measured milligrams per capsule, and a declared botanical source with the plant part used.

  • Preferred botanical sources: Rhaponticum carthamoides root and Cyanotis arachnoidea root carry the highest native ecdysterone content, roughly 1.5% and 4-5% respectively; Ajuga turkestanica is the practical source of turkesterone, at about 2.1% by weight.

  • Turkesterone claims warrant extra scepticism: independent mass-spectrometry profiling of marketed ecdysteroid supplements found declared content missing or far below label and turkesterone varying widely in standardised Ajuga turkestanica products; no human study has verified turkesterone content (Todorova et al., 2026).

  • Excipients matter: some products list hydroxypropyl-β-cyclodextrin (a solubility enhancer), which sits on the United States Department of Defense prohibited dietary-supplement ingredient list, making an otherwise permitted product off-limits for service members.

  • Compounding pharmacies are not a route: purified 20-hydroxyecdysone is an investigational drug held by Biophytis and is not available as a compounded prescription; pharmaceutical-grade material reaches individuals only through trial participation.

Practical Considerations

  • Time to effect: measurable change takes months, not weeks. Strength and body-composition differences emerged over 10-12 weeks of training, while walking-speed gains in older adults were assessed at six to nine months.

  • Common pitfall — trusting the label: the single most frequent error. Buying on labelled milligrams rather than an assay certificate carries a substantial chance of consuming an inert capsule, the most likely explanation for null results in practice.

  • Common pitfall — expecting steroid-like results: the verified effect sizes are modest increments on top of training, not a substitute for it. Every positive human result was recorded in people simultaneously training or rehabilitating.

  • Common pitfall — dosing once daily: a 2.4-4.9 hour half-life leaves most of the day at negligible exposure under once-daily dosing, and no positive trial used that schedule.

  • Common pitfall — treating turkesterone as ecdysterone: the two are distinct compounds with distinct evidence. Ecdysterone has controlled human trials; turkesterone has one acute study showing no change in growth factor or metabolic rate (Harris et al., 2024).

  • Regulatory status: sold as a dietary supplement in the United States and European Union with no pre-market efficacy requirement. Purified 20-hydroxyecdysone remains investigational, with no marketing authorisation anywhere.

  • Anti-doping status: ecdysterone has sat on the World Anti-Doping Agency Monitoring Program since 2020 and remains there for 2026, in and out of competition. It is not prohibited, but its use is being tracked.

  • Cost and accessibility: ordinary supplement pricing, typically USD 20-50 monthly. Batch-certified product costs more and is markedly harder to find, which is the real accessibility constraint rather than price.

Interaction with Foundational Habits

  • Sleep: no direct interaction is established, and no trial recorded sleep disturbance or improvement. The indirect consideration is formulational — ecdysteroid products are often sold in stimulant blends whose caffeine content does disrupt sleep, so a single-ingredient product taken in the evening is unlikely to interfere.

  • Nutrition: direct and consequential. Only 1-3% of ecdysterone from spinach or quinoa is absorbed (Isenmann et al., 2024), so food cannot substitute for supplementation; conversely, adequate dietary protein is a precondition, since the proposed mechanism raises protein synthesis and cannot act without substrate.

  • Exercise: potentiating, and probably required. Every positive human outcome occurred alongside structured resistance training or supervised rehabilitation, while sedentary aging mice showed no anabolic response at all (Lawrence et al., 2021). No advantage to timing doses around workouts has been tested.

  • Stress management: indirect and unresolved. Maral root preparations were classified as adaptogens in Soviet practice for fatigue resistance, and ecdysterone preserved liver energy metabolism under immobilisation stress in rats (Baev et al., 2022), but no human trial has measured cortisol, perceived stress or recovery.

Monitoring Protocol & Defining Success

Baseline testing establishes that the two organs most often blamed for supplement injury are healthy before exposure, and gives the reference points against which any later change is read. A sensible panel covers liver enzymes, kidney function, muscle enzymes, the sex-hormone axis, fasting glucose and insulin, and a lipid panel, together with an objective measure of the thing being targeted — body composition by dual-energy X-ray absorptiometry, grip strength, or a timed walk.

Ongoing monitoring is light, because the trials have found little to chase. Liver, kidney and muscle enzymes are repeated at 8-12 weeks, then every 6-12 months while use continues. The sex-hormone axis is re-tested once at 12 weeks to confirm the absence of suppression. Body composition and performance are re-measured at 12 weeks, since that is the horizon at which the human trials declared success or failure.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Alanine aminotransferase 10-26 U/L (men), 8-22 U/L (women) Detects liver injury from contaminants A liver enzyme released when liver cells are damaged. Conventional upper limit reaches 40-55 U/L, far above the functional target. Fasting sample preferred
Aspartate aminotransferase 10-26 U/L Separates a liver signal from a muscle signal A second enzyme found in both liver and muscle; rises with hard training independently of liver injury, so it is read alongside creatine kinase. Conventional upper limit reaches 35-40 U/L, well above the functional target
Creatine kinase 50-200 U/L Tracks muscle breakdown, the one documented serious event An enzyme released when muscle fibres rupture. The conventional upper limit reaches about 300-400 U/L in men, well above the functional target. Best drawn at least 48 hours after heavy training; 500-1000 U/L is common after exercise and not alarming alone
Creatinine and estimated glomerular filtration rate Above 90 mL/min/1.73 m² Renal clearance dominates elimination Creatinine rises with muscle mass, so cystatin C gives a better filtration estimate in trained individuals. The conventional threshold is 60 mL/min/1.73 m², far below the functional target
Total testosterone 600-900 ng/dL (men), 15-70 ng/dL (women) Confirms the claimed absence of hormonal suppression Morning draw before 10:00. The conventional male range starts near 300 ng/dL; the functional target sits in its upper half
Estradiol 20-30 pg/mL (men); no single target in cycling women — track change from the individual’s own baseline at the same cycle phase Tests whether the receptor mechanism produces a downstream hormonal effect The conventional male range runs to roughly 10-40 pg/mL, wider at both ends than the functional target. Requires the sensitive liquid-chromatography assay in men; standard immunoassays are unreliable at low concentrations
Sex hormone-binding globulin 20-40 nmol/L Shows whether free hormone shifted even when total did not A carrier protein for sex hormones. The conventional male range spans roughly 10-57 nmol/L, far wider than the functional target. Falls with insulin resistance, so it is read alongside fasting insulin
Fasting insulin Below 5 μIU/mL The metabolic outcome with the clearest human signal 12-hour fast, morning draw. Conventional ranges extend to 25 μIU/mL, far above the functional target
Fasting glucose 75-86 mg/dL Screens for the additive glucose-lowering effect flagged under interactions Paired with fasting insulin to compute an insulin-sensitivity index; the conventional cut-off is 100 mg/dL
High-sensitivity C-reactive protein Below 0.55 mg/L (men), below 1.0 mg/L (women) Tracks the anti-inflammatory claim A general marker of body-wide inflammation. Invalid within two weeks of infection or injury; the conventional cardiovascular cut-off is 3.0 mg/L
Lean body mass by dual-energy X-ray absorptiometry No established target; track change from the individual’s own baseline The primary claimed benefit, measured objectively Same scanner, same hydration state, same time of day. A change of roughly 1 kg is the smallest meaningful shift
400-metre gait speed Above 1.0 m/s The functional endpoint the pharmaceutical trial used Informative only in adults with existing mobility limitation; a 0.1 m/s change is the minimal clinically important difference

Qualitative markers worth tracking alongside the laboratory panel:

  • Training capacity — whether weekly volume tolerated rises at equal perceived effort
  • Recovery time between hard sessions, and the duration of muscle soreness afterwards
  • Energy stability across the day, particularly in the late afternoon
  • Sleep quality and time taken to fall asleep, as a check on stimulant contamination
  • Appetite and digestive comfort, the most frequently reported adverse-event category
  • Subjective ease of everyday movement — stairs, rising from a chair, carrying loads

Emerging Research

  • Combination with a weight-loss drug for muscle preservation: a phase 2 trial will give 20-hydroxyecdysone to 164 adults with obesity starting semaglutide, testing whether it protects lean mass during rapid weight loss (NCT07411378).

  • Prediabetes metabolic trial: an investigator-initiated study of phytoecdysterone in 34 adults with prediabetes, independent of industry sponsorship, would address the insulin-sensitivity signal; its registry record has stood at “Unknown” status since 2019 and no result has appeared (NCT03906201).

  • Anti-parasitic application: a phase 2/3 trial in 200 participants is testing 20-hydroxyecdysone against Giardia lamblia infection in Uzbekistan, an indication unconnected to the muscle literature and derived from traditional use (NCT04827537).

  • Completed sarcopenia trial awaiting confirmation: the phase 2b study that produced the walking-speed signal is complete; its per-protocol-only significance and 55% loss of end-of-treatment assessments mean a confirmatory phase 3 will settle the question (NCT03452488).

  • Neuromuscular disease extension: preclinical work combining 20-hydroxyecdysone with a gene-silencing drug in spinal muscular atrophy (an inherited disease in which the nerves controlling muscle degenerate) reported additive functional benefit, opening a disease indication distinct from age-related decline (Bézier et al., 2025).

  • Evidence that could weaken the case — negative animal work: phytoecdysteroids altered neither muscle mass nor protein-synthesis signalling in sedentary aging mice, directly contradicting the anabolic premise and still awaiting explanation (Lawrence et al., 2021).

  • Evidence that could weaken the case — product-content failures: a 12-week trial found under 1% of labelled content and no activity in cell culture, implying that much of the existing human literature may have tested placebos (Dissemond et al., 2025).

  • Dose-response and combination ratios: cell-culture work found additive muscle effects only at specific ecdysterone-to-diosgenin ratios, so ratio optimisation remains an open question no human study has yet approached (Kostov et al., 2024).

  • Bioavailability engineering: cyclodextrin inclusion complexes substantially raise oral and transdermal uptake, which matters because poor absorption is the leading explanation for the gap between cell-culture potency and human results (Wang et al., 2022).

Conclusion

Ecdysteroids are plant and insect steroids that appear to build muscle protein without acting on the male hormone receptor that conventional anabolic steroids use. That separation is the whole appeal, and the chemistry supports it: no trial has found the hormonal suppression that defines steroid use.

What the human record actually contains is thinner than the marketing implies. A purified form improved walking speed in older adults losing muscle, reduced breathing failure in severe pneumonia, and cleared a common intestinal parasite in athletes — each in a single study, and the first two run and largely written up by the company that owns the compound, a conflict of interest that the evidence base carries throughout. A small study found better blood-sugar handling and some fat loss alongside training. The muscle-building claim that drives sales rests on two content-verified studies against two that found nothing, though one of those used a product later shown to contain almost none of the labelled compound, and the other’s product was never tested.

That last point is the practical centre of this review. Most marketed products contain far less than they claim, some contain none, and a substantial minority carry an undeclared contaminant. Measurable adverse effects are scarce, and human exposure has never exceeded nine months. For someone training seriously and buying batch-certified material, the risk appears low and the possible gain real but modest and unconfirmed; for anyone buying on a label alone, the most likely outcome is nothing at all.

Top - Benefits - Risks - Protocol